SCHEMBL28598013

SCHEMBL28598013

Cc1ccc(-c2ccc3ccccc3n2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.50
PKM P14618 9/20 0.50
NPC1 O15118 8/20 0.50
RAB9A P51151 8/20 0.50
HPGD P15428 7/20 0.50
MAPT P10636 6/20 0.50
KMT2A Q03164 6/20 0.50
MEN1 O00255 5/20 0.50
HSD17B10 Q99714 4/20 0.50
TP53 P04637 3/20 0.50
HCRTR1 O43613 1/20 0.50
KDM4E B2RXH2 9/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
LMNA P02545 2/20 0.49
POLB P06746 4/20 0.48
MAPK1 P28482 2/20 0.48
MCL1 Q07820 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
PLIN1 O60240 1/20 0.48
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14269744 0.79 CYP1A2 (0.50) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL29082949 0.73 ALDH1A1 (0.47) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL29374931 0.73 RAB9A (0.64) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL170196 0.73 RAB9A (0.64) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL11497248 0.72 MMP2 (0.55) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL29746310 0.71 CYP11B1 (0.53) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL29580854 0.71 RAB9A (0.59) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL8783647 0.71 RAB9A (0.59) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL3647009 0.71 CYP11B1 (0.53) ALDH1A1PKMNPC1RAB9AHPGD
SCHEMBL20951334 0.71 TLR8 (0.50) ALDH1A1PKMNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074880-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF ST EUROPEO DI ONCOLOGIA S R L (IT) 2025-03-06 US disclosed
EP-4337640-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF Istituto Europeo di Oncologia S.r.l. (IT) 2024-03-20 EP disclosed
WO-2022238863-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2022-11-17 WO disclosed
EP-4089077-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF Istituto Europeo di Oncologia S.r.l. (IT) 2022-11-16 EP disclosed
CN-113185555-B Pincer-shaped manganese complex and preparation method thereof, related ligand and preparation method thereof, catalyst composition and application 河北农业大学 2022-11-11 CN disclosed
CN-113185555-A Pincer-shaped manganese complex and preparation method thereof, related ligand and preparation method thereof, catalyst composition and application 河北农业大学 2021-07-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074880-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF NDC1, CHD1L, NUMA1 ALDH1A1 4197/4885PKM 1559/4885NPC1 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.